Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nxera Pharma CoTSE:4565 +1.66%74 Median PS Value is 円2,778.75 as of Aug. 15, 2026, which is 100% below its 10-year median of 0.60. GuruFocus rates TSE:4565 with a GF Score™ of 74/100 and a GF Value™ of 円833.48 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 279 Biotechnology companies, Nxera Pharma Co ranks better than 72.4% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Nxera Pharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was 円328.609. Nxera Pharma Co's 10-Year median PS Ratio is 8.4561. Therefore, the Median PS Value for today is 円2,778.75.
As of today (2026-08-15), Nxera Pharma Co's share price is 円1105.00. Nxera Pharma Co's Median PS Value is 円2,778.75. Therefore, Nxera Pharma Co's Price to Median PS Value for today is 0.40.
The historical rank and industry rank for Nxera Pharma Co's Median PS Value or its related term are showing as below:
TSE:4565'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18 Med: 0.6 Max: 1.39
Current: 0.4
During the past 13 years, the highest Price to Median PS Value of Nxera Pharma Co was 1.39. The lowest was 0.18. And the median was 0.60.
TSE:4565's Price-to-Median-PS-Value is ranked better than 72.4% of 279
companies
in the Biotechnology industry
Industry Median: 0.64
vs TSE:4565: 0.40
Nxera Pharma Co (TSE:4565) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Nxera Pharma Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1105.00
/
2,778.75
=
0.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nxera Pharma Co Median PS Value Related Terms
Nxera Pharma Co Median PS Value Historical Data
* Premium members only.
The historical data trend for Nxera Pharma Co's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4565 vs VRTX, REGN, RVMD: Median PS Value Comparison
For the Biotechnology subindustry, Nxera Pharma Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nxera Pharma Co Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Nxera Pharma Co's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 8.4561.
Nxera Pharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円328.609.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nxera Pharma Co (TSE:4565) has a Median PS Value of 円2,778.75 as of Aug. 15, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Nxera Pharma Co and its competitors. This is 463025% above median its historical median of 0.60. Over the past decade, Nxera Pharma Co's Median PS Value has ranged from 0.18 to 1.39. According to the industry distribution chart, Nxera Pharma Co ranks #77 out of 279 companies in the Biotechnology industry, placing it in the top 27.6%.
Is Nxera Pharma Co's Median PS Value too high?
Nxera Pharma Co's current Median PS Value of 円2,778.75 is 463025% above median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 1.39. Based on the distribution chart, Nxera Pharma Co ranks #77 out of 279 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nxera Pharma Co has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nxera Pharma Co ranks #77 out of 279 companies for Median PS Value. This puts Nxera Pharma Co in the upper half of its industry. The industry median Median PS Value is 0.64. Historically, Nxera Pharma Co's own Median PS Value has ranged from 0.18 to 1.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.64, based on 279 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Nxera Pharma Co and its competitors. For the Biotechnology industry, the median Median PS Value is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nxera Pharma Co's current Median PS Value is 円2,778.75, which is 463025% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (TSE:4565) is currently considered Significantly Overvalued. The stock's GF Value™ is 円833.48, compared to a current price of 円1,105.00 — trading 32.6% above its estimated fair value. The current Median PS Value is 円2,778.75, which is 463025% above median its 10-year median of 0.60. Nxera Pharma Co's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Nxera Pharma Co (TSE:4565), the current Median PS Value is 円2,778.75 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nxera Pharma Co (TSE:4565) Overvalued in 2026?
Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be overvalued.
The current stock price of 円1,105.00 is trading 32.6% above its estimated GF Value™ of 円833.48.
GuruFocus considers Nxera Pharma Co to be Significantly Overvalued.
Key valuation signals for TSE:4565:
Median PS Value: 円2,778.75 (463025% above median its 10-year median of 0.60)
GF Value™: 円833.48 vs. price of 円1,105.00 (32.6% above fair value)
No single metric tells the full story. See the TSE:4565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
74GF Score
Get the complete analysis for TSE:4565
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4565 has been successfully added to your 
